Imagion Biosystems presented positive results from a phase I trial evaluating its experimental MRI contrast agent at the recent San Antonio Breast Cancer Symposium.
The company’s MagSense HER2 Imaging Agent (MSH2IA) was safe and well-tolerated in 13 patients diagnosed with HER2+ breast cancer, according to the findings. MSH2IA was designed as an adjunct to MRI for the assessment of axillary lymph node metastasis in patients diagnosed with HER2+ primary breast cancer.
The trial met its endpoints of safety and tolerability, and showed that blinded radiologists may be able to distinguish suspicious lymph nodes that are infiltrated with metastatic HER2+ cancer from those involved in a healthy immune response or otherwise normally reactive, the company said.
